Skin tissue engineering has emerged as a promising therapeutic strategy for severe wounds and inflammatory skin diseases. Stem cell-derived exosomes (SC-Exos) have recently gained increasing attention as cell-free therapeutic agents with regenerative and immunomodulatory potential, offering possible advantages over direct stem cell transplantation. To fully realize their therapeutic potential, however, efficient delivery platforms are needed to enhance local retention, preserve vesicle integrity, and support sustained release within the diseased skin microenvironment. In this review, we discuss advanced polymeric biomaterials as functional delivery platforms for SC-Exos in skin tissue engineering. We focus on natural and synthetic polymers engineered into nanofibrous scaffolds, hydrogels, and microneedles, and examine how these systems enhance exosome loading, protect vesicle integrity, improve local retention, and modulate release kinetics. We further highlight the therapeutic effects and underlying mechanisms of polymer–exosome systems in skin lesion repair, focusing on their roles in promoting angiogenesis, modulating local inflammation and immune responses, and facilitating extracellular matrix remodeling. Finally, we address remaining challenges and future directions for translating polymer-based SC-Exos delivery platforms into clinically relevant skin regenerative therapies.
Background: Atrial fibrillation (AF) remains a major clinical burden because structural and metabolic remodeling, particularly mitochondrial dysfunction and fibrosis, often persists beyond rhythm control. Human-relevant models that disentangle these axes and connect them to patient data are limited. Methods: Human atrial organoids were exposed to two AF-relevant stressors: rapid pacing (FP) and angiotensin II (AngII). We assessed mitochondrial and fibrotic remodeling by transcript/protein analyses, imaging, and contractility readouts, and benchmarked organoid responses against four public AF transcriptomic datasets (GEO: GSE128188, GSE138252, GSE222793, GSE239321). Statistical analyses used predefined contrasts versus matched controls with multiple-testing correction. Results: FP predominantly suppressed mitochondrial biogenesis/oxidative programs and increased stress-response features, resembling signatures observed in AF with heart failure (e.g., downregulation of mitochondrial regulators and altered cytochrome c patterns). AngII elicited stronger profibrotic signaling with a mixed mitochondrial response, mirroring profiles more typical of AF without heart failure. Both stressors impaired organoid contractility. Protein and immunostaining corroborated mitochondria–fibrosis crosstalk, with changes in PGC1α and cytochrome c alongside increased extracellular matrix deposition and myofibroblast markers (COL1A1, αSMA), consistent with stimulus-specific but partially overlapping remodeling trajectories. Conclusion: Distinct AF-relevant stressors drive divergent mitochondrial and fibrotic remodeling in human atrial organoids that recapitulate key features of patient datasets. These organoid models provide a translational platform to prioritize mitochondria-targeted and antifibrotic interventions and to inform biomarker development for residual dysfunction in AF.